Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
Public ClinicalTrials.gov record NCT03802630. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
Study identification
- NCT ID
- NCT03802630
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 450 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2, 2019 (Actual)
- Primary completion
- Jul 26, 2021 (Actual)
- Completion
- Jul 26, 2021 (Actual)
- Last update posted
- Jan 30, 2023
2019 – 2021
United States locations
- U.S. sites
- 26
- U.S. states
- 14
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Phoenix | Arizona | 85020 | — |
| Novartis Investigative Site | Mountain View | California | 94040 | — |
| Novartis Investigative Site | Santa Barbara | California | 93103 | — |
| Novartis Investigative Site | Colorado Springs | Colorado | 80909 | — |
| Novartis Investigative Site | Pensacola | Florida | 32503 | — |
| Novartis Investigative Site | St. Petersburg | Florida | 33711 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46280 | — |
| Novartis Investigative Site | New Albany | Indiana | 47150 | — |
| Novartis Investigative Site | Leawood | Kansas | 66211 | — |
| Novartis Investigative Site | Lenexa | Kansas | 66215 | — |
| Novartis Investigative Site | Stoneham | Massachusetts | 02180 | — |
| Novartis Investigative Site | Reno | Nevada | 89502 | — |
| Novartis Investigative Site | Bloomfield | New Jersey | 07003 | — |
| Novartis Investigative Site | Asheville | North Carolina | 28803 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28210 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44122 | — |
| Novartis Investigative Site | Monroeville | Pennsylvania | 15146 | — |
| Novartis Investigative Site | Abilene | Texas | 79606 | — |
| Novartis Investigative Site | Arlington | Texas | 76012 | — |
| Novartis Investigative Site | Austin | Texas | 78731 | — |
| Novartis Investigative Site | Austin | Texas | 78750 | — |
| Novartis Investigative Site | Bellaire | Texas | 77401 | — |
| Novartis Investigative Site | Houston | Texas | 77025 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | San Antonio | Texas | 78240 | — |
| Novartis Investigative Site | Madison | Wisconsin | 53705-3611 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03802630, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 30, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03802630 live on ClinicalTrials.gov.